Overview of Migristene

Property	Description
Active ingredient	Dimetotiazine mesilate (INN)
Form	Oral tablet
Pharmacological class	Antimigraine preparation, Phenothiazine derivative
Primary action	Dual Histamine H1 and Serotonin (5-HT) antagonist
Origin	Synthetic

What Type of Medicine is Migristene (Dimetotiazine)?

Migristene is a prescription-only pharmacological preparation whose active ingredient (INN) is Dimetotiazine mesilate, supplied in an oral tablet dosage form for systemic action. This compound is a synthetic single-ingredient formulation, structurally classified as a phenothiazine derivative. The World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system recognizes Dimetotiazine as an antimigraine preparation (ATC: N02CX05).

The drug's pharmacological identity is further defined by its specific, dual mode of action: it functions as a Histamine H1 receptor antagonist and a Serotonin (5-HT) receptor antagonist. While other phenothiazine compounds serve different therapeutic roles, Dimetotiazine is distinguished by its primary application in the modulation of neurochemical and vascular processes.

The Dual-Action Pharmacological Identity of Dimetotiazine

Dimetotiazine’s categorization as an antimigraine preparation is directly attributable to its dual antagonistic action on key chemical messengers. By simultaneously blocking the activity of both histamine and serotonin signals, it is intended to modulate the neurovascular and inflammatory processes often implicated in severe head discomfort. The drug's anti-migraine effect is associated with its serotonin antagonism.

This mechanism serves the general purpose of dampening overactive neurochemical signaling within the body. Its oral tablet form ensures systemic absorption, offering a therapeutic option for the symptomatic relief of complex discomfort that requires action against both histamine and serotonin triggers.

What side effects are possible with Migristene?

Possible Side Effects and Safety Information

The safety profile of Migristene (Dimetotiazine mesilate), a phenothiazine derivative, is defined by adverse reactions classified by government regulatory authorities into frequency categories and specific system-organ classes. The most commonly reported effects, which often reflect the medicine’s anticholinergic and sedative properties, include drowsiness, dry mouth, and constipation. A general feeling of malaise is typically classified as uncommon.

Documented Safety Patterns

The following high-level safety patterns are documented in regulatory labeling:

System-Organ Classes Affected: Adverse effects are officially listed across the Nervous System (drowsiness), Gastrointestinal Disorders (dry mouth, constipation), Renal and Urinary Disorders (difficulty urinating), Hepatobiliary Disorders, and Blood and Lymphatic System Disorders.
Serious Adverse Reactions: The regulatory profile documents the potential for rare but serious adverse reactions, including Agranulocytosis (a severe reduction in white blood cells) and Hepatic Dysfunction, which may present as jaundice.
Population-Specific Considerations: Regulatory documents note that older adults may be more susceptible to adverse effects, particularly drowsiness and difficulty urinating. Caution is also specified for patients with pre-existing conditions such as glaucoma or prostatic hypertrophy due to the drug’s properties.
Exposure-Related Notes: Some adverse effects may be more pronounced at the start of treatment. Additionally, the sedative effects of the medicine may impair mental and physical abilities, requiring caution during activities like operating machinery. Safety restrictions also limit use in individuals with known hypersensitivity to any phenothiazine derivative.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Dimetotiazine mesilate (Migristene) is defined by its pharmacological classification as a phenothiazine derivative and H1/5-HT antagonist. The manifestations described in regulatory documents are potentially severe, requiring immediate medical intervention.

Overdose may present with a complex set of clinical signs, including profound drowsiness, delirium, confusion, uncoordinated movement, and seizures due to Central Nervous System (CNS) toxicity. Systemic signs include dangerous hypotension (low blood pressure) and tachycardia. Due to the documented risk of life-threatening cardiac rhythm disturbances, continuous electrocardiographic monitoring is required.

Required Emergency Actions

Any suspected overdose is a medical emergency that requires immediate medical attention. Regulators explicitly state that if severe, life-threatening symptoms, such as significant respiratory distress or cardiac arrhythmia, occur, emergency services must be contacted immediately.

Management and Monitoring

No specific antidote is known for this drug class. Management is therefore strictly symptomatic and supportive, focusing on maintaining vital functions. This includes the administration of activated charcoal to reduce absorption and IV benzodiazepines to control seizure activity. Constant cardiac monitoring and serial ECGs are essential components of management.

Therapeutic Uses of Migristene

What Migristene Treats: Main Uses and Benefits

Symptomatic Management of Neurovascular Headaches

The medication is commonly used in conditions characterized by periods of heightened symptoms related to neurovascular disorders, and is commonly used to help with managing migraine and tension headaches. This use focuses on providing symptomatic support for the recurring, intense head discomfort.

Easing Acute Symptoms and Recurrent Patterns

This medication is used in the symptomatic management of headache onset and is typically applied in managing these acute and recurrent pain patterns. It helps address symptom clusters that may become intense or disruptive, and is applied to help ease the distress of severe, pulsating pain episodes. Clinically, the medication is relevant for a focused spectrum of discomfort, which includes managing migraine, tension-type headache, and specific headaches associated with gynecologic disorders. This use provides support that helps ease the overall symptom burden during difficult episodes.

“The primary benefit of this medication is its supportive role in mitigating severe, recurring head discomfort and improving comfort during symptomatic periods.”

Quick Fact: Relief for Severe, Recurrent Head Pain The drug supports functional stability and helps patients cope more steadily when symptoms interfere with routine activities.

The overall goal is to assist with maintaining functional stability and supports improved day-to-day comfort during symptomatic periods.

Regulatory References

Drug Information Sheet issued by a Japanese regulatory body

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Migristene

Official regulatory documents define the population eligibility for Migristene (Dimetotiazine mesilate) through absolute prohibitions and mandatory cautious use for specific groups.

Populations for whom use is contraindicated (must not use):

Patients with a known hypersensitivity or allergic reaction to any phenothiazine derivative (the drug's class).
Individuals with a history of bone marrow suppression or certain blood dyscrasias.
Patients in comatose states or those with severe cardiovascular disorders.
Patients presenting with lower respiratory tract symptoms, including asthma, as stated in the label for this class.
Pediatric patients less than two years of age are excluded.

Age and Condition-Specific Eligibility Rules:

Population Group	Regulatory Status
Infants (<2 years)	Contraindicated
Elderly (Geriatric)	Caution is required due to increased susceptibility to effects like sedation and potential for orthostatic hypotension.
Hepatic Impairment	Caution is required for use in patients with impaired liver function.
Pregnancy / Lactation	Conditional use only after a formal risk/benefit assessment by a healthcare professional; use may be avoided in the first trimester.

The regulatory status is primarily derived from established prescribing information and Phenothiazine class warnings, strictly defining who may be considered eligible for treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Migristene (Dimetotiazine mesilate) as defined by authoritative government regulatory sources.

Interaction Scope

The interaction profile for Dimetotiazine is primarily structured by a single substance-specific pharmacodynamic effect. Regulatory labeling explicitly addresses potential interactions with Alcohol (Ethanol). Co-administration of the medicine with Alcohol may result in the enhancement of the drug's effects or its adverse reactions. This documented interaction establishes a specific constraint against the simultaneous use of this substance.

Interaction Category	Officially Documented Status
Formal Contraindications	None explicitly documented in available regulatory sources.
Metabolic Interactions	None explicitly documented (e.g., no specific CYP enzyme involvement noted).
Timing Requirements	None officially documented (No mandatory dosing separation windows specified).

Official Interaction Structure

The official interaction profile is defined by the constraint with Alcohol, categorized as a pharmacodynamic enhancement of the medicine's effects or adverse reactions. Available regulatory documents do not specify any explicit drug-drug contraindicated combinations or explicit restrictions related to pharmacokinetic interactions, such as those mediated by Cytochrome P450 enzymes or drug transporters. The full regulatory framework for this section is therefore based solely on the documented risk of enhanced pharmacological effect when co-ingested with Ethanol.

Mechanism of Action

Migristene functions as a selective antagonist at the 5-HT1 B and 5-HT1 D receptor subtypes. This dual action facilitates the compound's biochemical effect by modulating the activity of the trigeminovascular system.

By binding to and blocking these specific receptors on presynaptic terminals, Migristene consequently reduces the release of calcitonin gene-related peptide (CGRP). CGRP is a neuropeptide involved in vascular processes and nociception.

The compound's primary physiological consequence is to inhibit smooth muscle contraction in cranial blood vessels and modulate afferent nociceptive signaling within the central nervous system. This action describes the drug's mechanism at the tissue and system level.

Dosage and Administration Information

How to Use Migristene: Official Administration Guidelines

This section outlines the administration guidelines for Migristene (dimetotiazine). Patients must follow the specific dosing instructions prescribed by a healthcare professional.

Administration Scope and Rules

Administration Detail	Standard Guidelines
Route of Administration	Internal (Oral Tablet)
General Dosing (Adults)	One tablet (20 mg of dimetotiazine) at a time, three times a day.
Dose Adjustment	The dosage may be adjusted by a physician according to the disease, age, and symptoms. In severe cases, the dose may be increased up to a maximum of six tablets (120 mg) per day as needed.
Timing	Not explicitly stated in relation to meals.
Preparation	None stated; administered as an intact tablet.
Age-Specific Rules	Dosing is specified in general for adults; physician adjustment is permitted based on age.
Adherence Requirement	Patients must strictly follow the instructions.

Missed Dose Instructions

If a dose is missed, take the dose as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Patients should never take two doses at one time.

Procedural and Cessation Requirements

Do not stop taking this medicine unless a doctor instructs you to do so.
If more than the prescribed dose is accidentally taken, a doctor or pharmacist must be consulted immediately.

Recent Clinical Evidence

Research evidence / Overview of studies for Migristene

Evidence for Symptomatic Management of Migraine

Research on Dimetotiazine mesilate has been explored in studies concerning symptomatic patterns related to conditions characterized by episodes of heightened symptoms, such as migraine. The evidence base relies on historical clinical trials and summaries from regulatory authorities that document the medication’s inclusion in treatment protocols. Due to its classification as a Phenothiazine derivative, the research landscape also incorporates systematic reviews that explored the effects of related compounds for acute symptomatic patterns. Researchers monitored outcomes related to physical discomfort, tracking measurements of pain severity and assessing the attainment of pain-free status in trials examining acute symptoms in adult populations. Research reports patterns regarding symptomatic change in patients presenting with episodic headache patterns.

Evidence for Tension-Type Headaches and Associated Headaches

Dimetotiazine was evaluated in research exploring its use in conditions characterized by fluctuating manifestations such as tension-type headaches. This usage was studied based on historical trials and regulatory documentation. Studies explored outcomes related to physical discomfort, measuring changes in head discomfort levels during symptomatic periods. Evidence also describes patterns observed in research focusing on episodes where symptoms become more noticeable, such as those headaches linked to gynecologic disorders. The evidence base for this specific context is limited, primarily derived from clinical observations rather than dedicated, large-scale clinical research.

Long-Term Evidence and Characterization of Follow-up

Research on Dimetotiazine primarily focused on the measurement of short-term symptomatic patterns related to acute discomfort. Follow-up durations were constrained to short observation periods. Long-term effects are not fully established by publicly detailed clinical trials, and there is limited information regarding the durability of response when the medication was observed over defined time intervals.

Evidence Gaps and Areas of Uncertainty

The research landscape highlights key areas where more understanding is needed. The quality of historical evidence varies across studies. Research lacks studies that directly compare the medication in modern trials against current headache treatments. Data for certain groups, such as children (pediatric patients) and older adults, remain insufficient, meaning the results apply only to the populations studied. Dedicated, modern trials for this specific older drug data are still emerging slowly.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Migristene (FAQ)

Q: Is Migristene meant for acute treatment or prevention of migraines?

According to official product information, Migristene is used in the treatment of migraine and tension headaches. Its mechanism involves inhibiting the constriction of cerebral blood vessels, which works to help prevent the progression of headache symptoms. This action is typically associated with the acute or symptomatic treatment of a headache attack.

Q: Does Migristene help with symptoms besides the headache pain?

As a medication belonging to the phenothiazine derivative class, Migristene is noted in its pharmacological profile to possess antiemetic (anti-nausea) properties. This suggests the drug's properties may assist with certain non-pain symptoms associated with migraine attacks.

Q: Is the mechanism of action of Migristene fully understood by researchers?

While the primary mechanism is detailed in regulatory documents, official research summaries acknowledge evidence gaps and limited long-term data. These summaries state that there are areas of uncertainty, particularly concerning long-term effects and direct comparisons with modern treatments.

Q: Why does Migristene only affect the migraine and not other pain?

The drug's action is highly specific to the trigeminovascular system, which is the pathway primarily involved in the mechanism of migraine attacks. By modulating afferent nociceptive signaling within this system, the medicine targets pain pathways specifically associated with migraine, rather than general body pain.

Q: Does Migristene interact with common over-the-counter pain relievers like ibuprofen?

Regulatory documents describing the drug's interaction profile do not specify explicit contraindicated combinations with common over-the-counter pain relievers such as ibuprofen. If you have questions about specific medications, refer to the full regulatory information.

Q: Are there known interactions between Migristene and antidepressants (SSRIs/SNRIs)?

Official regulatory documents detailing the drug's known interaction profile do not specify explicit contraindicated combinations with common antidepressant medications like SSRIs or SNRIs. If you have concerns about specific prescription combinations, refer to the full regulatory information.

Q: Does Migristene interact with any common supplements like magnesium or CoQ10?

The official interaction profile, which focuses on drug-drug and substance-specific interactions, does not specify explicit contraindicated combinations with common dietary supplements.

Q: Does Migristene have any documented effect on blood pressure or heart rate?

Regulatory documents note the potential for certain effects on circulation, particularly in older adults. For this specific population, there is a recognized potential for orthostatic hypotension, which is a drop in blood pressure when standing up.

Q: Can Migristene cause issues with stomach upset or nausea?

Gastrointestinal disorders are included in the officially documented system-organ classes affected by adverse reactions. Reports associated with Dimetotiazine mesilate have mentioned the potential for individuals to experience nausea or general stomach upset.

Q: Is it true that Migristene has fewer cardiovascular risks compared to older drugs?

Research summaries compiled for regulatory purposes indicate a lack of modern studies that directly compare the cardiovascular risk profile of this medication against newer headache treatments. Therefore, official documents do not contain a comparative statement about having fewer cardiovascular risks than older drugs.

Q: Can Migristene be used by teenagers or children?

The use of Migristene is contraindicated (must not be used) for pediatric patients under two years of age. For those older than two, official instructions note that the dosage may be adjusted by a physician according to the child's age, disease, and symptoms.

Q: Can people with liver or kidney issues use Migristene?

The regulatory profile specifies that caution is required for use in patients with pre-existing impaired liver function. However, specific mandatory cautions related to kidney impairment (renal function) are not explicitly detailed in the core authoritative documents.

Q: Can Migristene be used in combination with other preventive migraine medicines?

Official regulatory documents do not specify explicit contraindicated combinations when used alongside other preventive migraine medicines. The official interaction profile is primarily structured around alcohol and specific population cautions.

Q: Why do people sometimes report stopping the use of Migristene?

Reasons for cessation, as indicated by the regulatory safety profile, may be related to both common and serious adverse reactions. Common effects include drowsiness and dry mouth. Cessation may also be linked to the potential for rare but serious adverse reactions, such as agranulocytosis or hepatic dysfunction.

Q: How is Migristene different from older migraine treatments like triptans?

The drug’s distinct profile is defined by a dual antagonistic action on key chemical messengers. It functions as both a Histamine H1 receptor antagonist and a Serotonin ( 5-HT) receptor antagonist. This dual mechanism differentiates its overall pharmacological effect from other antimigraine preparations.

Q: What are the key conditions Migristene is approved to treat?

Official regulatory labeling clearly states the medicine is used in the treatment of migraine and tension headaches. This classification establishes the primary, approved therapeutic indications for the product.

Q: Is Migristene typically used for people with chronic migraines?

Regulatory authorities have documented the use of this medicine in the population of patients with chronic migraine. This is evidenced by a post-marketing use-results survey that covered individuals with this condition, indicating its use is a subject of evaluation and monitoring.

Q: Is Migristene considered a controlled substance?

Dimetotiazine mesilate is classified as a prescription-only pharmacological preparation. Official naming and status documents confirm that it is not categorized as a scheduled or controlled substance.

How should Migristene be stored and disposed of?

The official regulatory documents specify strict storage and disposal requirements for Migristene (Dimetotiazine mesilate) tablets.

Storage Requirements

Migristene must be stored at room temperature, specifically maintained between 1 C and 30 C (33.8 F and 86 F). The product requires mandatory protection from direct sunlight and moisture to preserve its labeled stability, which is generally three years from manufacture. It is a mandatory requirement that the medicine be kept out of the sight and reach of infants and children.

Disposal Instructions

Unused or expired Migristene must be disposed of in accordance with local laws and regulations. To prevent environmental contamination, the medicine must not be discarded through wastewater or inappropriate general household trash. Discarded product should be returned to a pharmacy or designated collection program for proper handling as pharmaceutical waste.

Migristene